Abstract

Positron emission tomography magnetic resonance imaging (PET/MRI) is an innovative approach that combines the strengths of PET and MRI to enhance the diagnostic accuracy of imaging. MRI creates an intrinsic contrast using the magnetic properties of hydrogen protons, but this intrinsic contrast may not always provide sufficient diagnostic information. To address these shortcomings, MRI contrast agents are used in a complementary and supportive role. Paramagnetic and superparamagnetic MRI contrast agents have different magnetic properties and are preferred for various clinical conditions. The clinical use of contrast agents enables more sensitive diagnostic and personalized treatment approaches based on both anatomical and functional information. Today, hybrid contrast agents developed for PET/MRI systems promise more advanced diagnostic performance compared to other imaging methods, especially in the diagnosis of oncological and cardiovascular diseases, and offer imaging capabilities at the molecular and cellular levels, providing new opportunities in diagnosis and treatment processes.